The nerve agents are extremely toxic organophosphates which lead to massive inhibition of acetylcholinesterase (AChE) in both the central and peripheral nervous systems. The currently approved pyridinium oxime reactivators of organophosphate-inhibited AChE (eg, 2-PAM in the United States) cannot penetrate the blood-brain barrier because of the permanent positive charge in the pyridinium ring. Therefore these current oximes cannot rescue inhibited AChE in the brain. Our laboratories have invented and patented a platform of substituted phenoxyalkyl pyridinium oximes that have been tested for efficacy as therapy within the brains of adult male rats which were challenged with a high sublethal dosage of highly relevant surrogates of sarin (nitrophenyl isopropyl methylphosphonate, NIMP) and VX (nitrophenyl ethyl methylphosphonate, NEMP). The histochemical astrocyte marker glial fibrillary acidic protein (GFAP) was investigated as an indication of neuropathology in two brain regions, the piriform cortex and the dentate gyrus of the hippocampus, which are regions known to be damaged by nerve agent toxicity. Rats treated with either NIMP or NEMP without therapy or with NIMP or NEMP plus 2-PAM therapy showed similar increases in GFAP compared with vehicle controls. However, the rats challenged with NIMP or NEMP plus therapy with our novel Oxime 20 (either a bromide or a mesylate salt) showed GFAP levels statistically undistinguishable from controls. These data provide highly supportive functional evidence of novel oxime entry into the brain. These novel oximes have the potential to provide central neuroprotection from organophosphate anticholinesterase-induced damage, which is a characteristic not displayed by most pyridinium oximes.
The threat of poisoning by organophosphates (OPs), both nerve agents and insecticides, exists for both military and civilian populations, and recent world events illustrate the danger from assassins and leaders of rogue nations (Hay, 2018; Hoffman et al., 2007; Loveluck, 2017; Swenson, 2017) . Exposure to OPs causes inhibition of acetylcholinesterase (AChE), with excess acetylcholine (ACh) leading to hypercholinergic activity within the brain followed by glutamate-mediated excitotoxicity and seizures, which, if prolonged or recurrent, result in brain damage (Marrs, 1993; McDonough and Shih, 1997) . Current therapy includes atropine to block peripheral muscarinic ACh receptors, an oxime, eg, 2-PAM, to reactivate inhibited AChE, and a benzodiazepine anticonvulsant (Marrs, 2004; Marrs et al., 2007) . However, traditional pyridinium oximes like 2-PAM (Johnson et al., 1992; Lorke et al., 2008) cannot effectively cross the blood-brain barrier (BBB) because of the permanent positive charge (Persidsky et al., 2006) . The brain remains vulnerable to long-term damage, which may cause behavioral alterations and neurological and cognitive deficits, as seen in victims of the Tokyo terrorist attacks with sarin (Hoffman et al., 2007; Yamasue et al., 2007; Yanagisawa et al., 2006) .
Our laboratories have invented a platform of lipophilic substituted phenoxyalkyl pyridinium oximes (U.S. Patent 9,227,937). The reactivation efficacy testing was done using highly relevant nerve agent surrogates for sarin (4-nitrophenyl isopropyl methylphosphonate, NIMP) first described by Ohta et al. (2006) and VX (4-nitrophenyl ethyl methylphosphonate, NEMP) first described by Fukuto and Metcalf (1959) and characterized in our laboratories (Chambers et al., 2013; Meek et al., 2012) . Oximes demonstrating in vitro efficacy were tested in vivo in a rat model, and several showed a reduction of brain AChE inhibition following NIMP or NEMP challenge, whereas 2-PAM did not (Chambers et al., 2013) . These in vivo tests used a paradigm of oxime delivery at the time of peak brain AChE inhibition (about 1 h) when the OP was in the process of being cleared. Therefore, a reduction in brain AChE inhibition could not result from only peripheral AChE reactivation. Of the several efficacious oximes, Oxime 20 (Figure 1 ) displayed the greatest effect and it is the subject of this study.
Glial fibrillary acidic protein (GFAP) was investigated as a marker of brain damage. GFAP is a type III intermediate filament found in astrocytes in the brain, and is involved with interactions between astrocytes and neurons. Neuronal injury or inflammation induces cellular signaling in astrocytes to increase the expression of GFAP; consequently high levels of GFAP can lead to astrogliosis that may result in glial scarring (Chen et al., 2005; Collombet et al., 2007) , and are linked to neural damage and potential neurodegeneration (Benkovic et al., 2006) .
In this study after rats were exposed to each nerve agent surrogate, elevated expression of GFAP was used as a marker to indicate neurological damage in the brain (Otani et al., 2006) . Likewise, lack of overexpression of GFAP in animals treated with surrogate plus novel oxime indicated neuroprotection. In addition, in vivo administration of kainic acid (KA) served as a positive control for method verification, for both the characterization of stages of seizure-like activity and the effectiveness of our staining methodology for observing neurological damage, as KA, an agonist of the kainate receptor, induces seizures and elevated expression of GFAP (Milenkovic et al., 2005; Schmued et al., 2005) . KA causes overstimulation of the glutamatergic system and induces epileptic-type seizures and neural damage similar to the effects of nerve agents (Hopkins et al., 2000; Riljak et al., 2007) .
The hippocampus, an area known to be involved in the memory process, is an area likely to be affected by exposure to the nerve agent surrogates (Lee et al., 2004; Otani et al., 2006) . The second area of interest was the piriform cortex, which is one of the regions involved in the propagation and spread of seizure activity (Chapman et al., 2006) , and was expected to show the earliest neural damage. Therefore, an evaluation of neural damage resulting from the surrogates was evaluated in the dentate gyrus region of the hippocampus and in the piriform cortex, both of which have been documented as suffering damage from nerve agents (Myhrer et al., 2007 (Myhrer et al., , 2010 and KA (Djebaïli et al., 2001; Riljak et al., 2007) . From our library of over 100 novel oximes, Oxime 20 was selected and evaluated for its neural protective capabilities in two forms, the original bromide salt and the mesylate salt. The mesylate was expected to display better druggability (ie, solubility, bioavailability, and shelf-life) than the original bromide salt. The hypothesis for the study was: Novel Oxime 20, but not 2-PAM, would be capable of protecting the brain of rats from structural damage induced by surrogates of the nerve agents, sarin and VX. In this study protection attributed to novel Oxime 20 from potential neurodegeneration was evidenced by a reduction in GFAP expression, compared with nerve agent surrogates either alone or followed by 2-PAM therapy.
MATERIALS AND METHODS
In vivo testing of oxime efficacy. Adult male Sprague Dawley rats (about 250-350 g; initially obtained from Charles River Laboratories, subsequently from Envigo) were used for the in vivo tests. Rats were maintained in an AAALAC-accredited facility with a 12 h/12 h light/dark cycle and with standard laboratory rat chow and tap water available ad libitum. All procedures were previously approved by the Institutional Animal Care and Use Committee of Mississippi State University.
Rats were administered a single high sublethal challenge IP of a nerve agent surrogate (NIMP, 0.325 mg/kg; NEMP, 0.4 mg/kg; both in neat DMSO vehicle, 1 ml/kg body weight), which induced signs of cholinergic toxicity and seizure-like behavior, and inhibited about 80% of the brain AChE compared with vehicle controls after 1 h (Chambers et al., 2013; Meek et al., 2012) . This time point yielded peak inhibition, and at this time an IM injection of oxime (Oxime 20 or 2-PAM; 100 mmoles/kg in DMSO, 0.5 ml/kg body weight) was administered. This dosage was used in previous studies to demonstrate novel oxime efficacy in reducing brain AChE inhibition (Chambers et al., 2013) . The mesylate salt of Oxime 20 (abbreviated as 'OxMS') was administered at the same molar equivalent dosage and by the same method as the bromide salt of Oxime 20, except 0.9% saline was used as the vehicle because of the mesylate's higher aqueous solubility. Vehicle controls were also included. Animals were continuously monitored for seizure-like activity, using a modified Racine scale: (0) normal behavior; (1) oro-alimentary movements and head nodding; (2) anterior limb clonus and head nodding; (3) loss of balance, jumping, and running; (4) tonic convulsions; (5) death. Some animals were later euthanized at 30 or at 120 min post-oxime injection to confirm levels of AChE inhibition and reactivation. The brain was rapidly dissected from the skull. Half of each brain was homogenized at 40 mg/ml in 0.05 M Tris-HCl buffer (pH 7.4 at 37C). Cholinesterase activity in the brain was assayed spectrophotometrically by our modification of the Ellman method using acetylthiocholine as the substrate and 5,5 0 -dithio-bis(nitrobenzoic acid) as the chromogen, with eserine in the blanks to correct for non-AChE hydrolysis of substrate (Chambers and Chambers, 1989; Ellman et al., 1961) . The inhibition of AChE by the OP and reactivation by the oxime were calculated by comparing with the negative (vehicle only) and positive (OP only) controls, respectively. The same dosages and treatment modalities of OP and oxime were also used in an additional cohort of animals analyzed for neural damage in the brain; however, longer time points were selected to allow for a time course analysis of physiological/structural damage induced by the nerve agent surrogates. Characterizing the OP-induced neural damage, as evidenced by GFAP immunohistochemical staining, was done by analyzing damage at 2, 4, or 7 days post-OP challenge.
To verify the immunohistochemical damage, additional rats were treated IP with KA (10 mg/kg in 0.9% saline; 2 ml/kg body weight) to yield seizure-induced neural damage and to establish a benchmark for GFAP expression (Schmued et al., 2005) . Animals were monitored for seizure-like activity and were sacrificed 2 and 4 days post-injection with KA, and the brains were processed for neural damage using GFAP immunohistochemistry.
Immunohistochemistry. Brains from rats treated with OP (NIMP or NEMP), oxime, OP plus oxime, or vehicle control were collected, and immediately rinsed with ice cold saline and cut in half sagittally. The left half of the brain was snap frozen in liquid nitrogen, and was later utilized to determine AChE activity. The right brain half was hand-dissected into two regions (one containing striatum/piriform cortex, and the other containing the hippocampus/amygdala) and placed into 10% neutral buffered formalin for 3 days at 4 C to fix the tissue. The formalin was then removed and a 25% sucrose solution in phosphate buffered saline (PBS) was added as a cryoprotectant of the brain tissue. The sucrose solution was removed after the tissue sections had equilibrated with the sucrose solution (2-3 days) and the brain sections were frozen by immersion into isopentane on dry ice. The cryoprotected tissue was then stored at À80 C until sectioning. The staining protocol was modified from an existing published protocol Pringle et al., 2008) . The brains were sectioned at 25 lm using a Richard Allen Scientific cryostat set at À10 C, with each collected slice placed into a well of a 24-well plate (kept on ice) containing 0.01 M PBS, and then stained for GFAP expression. The sections were first incubated in a 3% blocking solution of goat serum in 0.01 M PBS for 2 h at room temperature (22 C) on a horizontal shaker/rocker. The blocking solution was removed and control or primary antibody solution (1:1000 GFAP; Chemicon AB5804) was then added and incubated overnight on a rocker at 4 C. The sections were rinsed 3 times (separated by 10 min) in diluent, and then a fluorescent secondary antibody (1:800 Dylight 488; Thermo-Fisher) was added and the slices were incubated at 22 C for another 2 h in the dark. The sections were then washed 3 times in diluent, and mounted using a free floating technique to glass slides that had been treated with poly-L-lysine to promote adherence. An additional step was performed on some slices to verify cell nucleus location. These sections were incubated in 4 0 ,6-diamidino-2-phenylindole (DAPI; fluorescent DNA stain; blue) solution on the slide for 10 min, and then rinsed 3 times in PBS. The slides were then cover-slipped, and stored at 4 C until imaged for GFAP luminosity.
Images were taken using an Olympus BX51 microscope with appropriate fluorescent filters and an integrated camera. Pictures were taken of the dentate gyrus and piriform cortex regions of the brain using the 20Â objective on the microscope. The saved images were then analyzed for GFAP expression using the ImageJ software (obtained from NIH). The background was subtracted from the images and a region of interest (ROI) was set at a fixed size. The ROI was randomly overlaid on cells that were exhibiting expression of GFAP, and the levels of luminosity were determined and depicted as integrated density. These values were used to quantify the GFAP expression levels of each of the samples.
Statistical analyses. Significant differences in the in vivo AChE activity data (comparing the 30 min and 2 h time points) were analyzed using the Student t test (Sigmastat Software), with p .05 indicating significant differences.
For the GFAP data, one-way analysis of variance (ANOVA) was used to test differences among treatment groups, with p .05 indicating significant differences (SigmaStat Software). Tukey's post hoc test was used when treatment groups were found to be significantly different from one another. Three to four animals were used for each treatment group, and 30 regions of interest (ROI; ten from three different slices) were collected from each animal during imaging.
RESULTS
For the in vivo experiments, both NIMP (0.325 mg/kg) and NEMP (0.4 mg/kg) were effective AChE inhibitors, with peak inhibition (80% of brain AChE) occurring 1 h post IP injection with the nerve agent surrogates, similar to previous results (Chambers et al., 2013; Meek et al., 2012) . Both OP's initiated seizure-like activity at these dosages. Cholinergic signs of toxicity and seizure-like activity began at about 20-30 min and at peak AChE inhibition (1 h) consisted of both fore and hind limb muscular shaking/rigidity, head bobbing, and accompanied by salivation/ lacrimation. Rats treated with KA, the positive methodological control, displayed seizure-like activity that appeared similar to that induced by the surrogates within 30 min of injection. Antidote was administered at time of peak AChE inhibition (1 h post OP). Rats treated with NIMP or NEMP all scored a 3 on the toxicity scale prior to oxime administration. At 2 h following Oxime 20 administration rats were scored a 1 on the toxicity scale, whereas rats receiving vehicle or 2-PAM were scored a 3. At 24 h and later, all rats were scored as normal (0).
When administered (IM injection; 100 mmol/kg) at peak AChE inhibition, both the bromide and the mesylate salts of Oxime 20 were equally capable of reactivating appreciable levels of AChE inhibited by NIMP and NEMP in the brain. At 30 min, 25% of inhibited AChE had been reactivated, and by 2 h, the level of reactivation increased to 35%, and these values were not significantly different between surrogates (NIMP vs NEMP; Figure 1 ). For comparison, treatment with the traditional oxime, 2-PAM, yielded no reactivation in the brain. On 4 days following treatment, there was 20%-30% inhibition of brain AChE in NIMPtreated rats but no inhibition remaining in NIMP plus Oxime 20-treated rats (data not shown).
Rats treated with KA displayed similar patterns of seizurelike behavior observed in the surrogate-challenged rats, and after 2 and 4 days, GFAP expression was significantly (p < .001) elevated compared with control animals in the piriform cortex (Figure 2) . Expression of GFAP was also significantly (p < .05) elevated in KA treated rats compared with controls at 2 days in the dentate gyrus region of the hippocampus (data not shown).
Administration of the VX surrogate, NEMP, significantly (p < .001) increased GFAP expression in the piriform cortex compared with controls at 2 and 7 days after treatment (Figure 3) . After 4 days treatment, both surrogates (NIMP and NEMP) yielded significantly (p < .05) elevated GFAP, and surrogate plus Oxime 20 treatment reduced GFAP expression to near control levels in both the piriform cortex and the dentate gyrus region of the hippocampus (Figs. 4 and 5) . This same pattern of reduced GFAP expression was also found for the mesylate salt of Oxime 20 in both brain regions (Figure 6 ). The expression of GFAP in both the piriform cortex and the dentate gyrus after 4 days was similarly elevated in rats treated with NIMP only and with NIMP plus 2-PAM (Figure 7 ).
DISCUSSION
Both nerve agent surrogates (NIMP and NEMP) were effective inhibitors of brain AChE, and the seizure-like activity displayed similar stages to that induced by KA, and is assumed to be similar to the seizures that nerve agents produce because the surrogates leave the AChE phosphylated with the same chemical moieties as their respective nerve agents (Meek et al., 2012) . The levels of inhibition of brain AChE after exposure to the nerve agent surrogates were similar to levels in other studies using live nerve agents, as well as other surrogates for nerve agents. For example, Zaja-Milatovic et al. (2009) observed similar seizure activity and levels of AChE inhibition using the soman surrogate diisopropylphosphorofluoridate (DFP) in rats as was detected using the surrogates in the present research.
Higher expression of GFAP indicates the activation of astrocytes and the potential for neural structural damage occurring at a later time, resulting in neurodegeneration. Both surrogates as well as KA were found to elevate GFAP levels in the same brain regions, the piriform cortex and the hippocampus, as regions known to be involved in the propagation and spread of seizures (Aroniadou-Anderjaska et al., 2009; Myhrer et al., 2010) . These data are consistent with the findings of Schmued et al. (2005) , where both of these brain regions in mice exhibited neural degeneration after treatment with KA, as evidenced by significantly higher levels of GFAP and positive staining for FluoroJade C (Schmued et al., 2005) . Extensive damage was also seen by Riljak et al. (2007) in the dentate gyrus region of the hippocampus of rats treated with KA, consistent with our data. Also, in studies by Damodaran et al. (2002 Damodaran et al. ( , 2006 evaluating global changes in gene expression after exposure to sarin in Sprague Dawley rats, the gene for GFAP was found to be elevated after exposure to the nerve agent in several brain regions within 1-2 h and persisted for at least 7 days. These data are also consistent with the changes that were observed in this research using GFAP as a marker for neural damage.
In this study animals that were treated with surrogate plus Oxime 20 (either the bromide or the mesylate salt) showed protection against potential neural damage, as indicated by lower GFAP expression, similar to the vehicle controls, compared with surrogate alone challenged animals. Importantly, seizure-like activity also diminished soon after the administration of Oxime 20, similar to our earlier report conducted on rats challenged with lethal levels of the surrogates (Chambers et al., 2016) . In addition, no protection was provided by the currently approved oxime therapeutic, 2-PAM, as evidenced by no GFAP expression difference between surrogate versus surrogate plus 2-PAMtreated animals. The degree of seizure-like activity in these animals also remained unchanged after 2-PAM was administered compared with non-oxime treated animals which were challenged with either surrogate. These behavioral and histochemical data are consistent with the early neurochemical data, indicating no early reactivation of inhibited AChE in the brain at 30 min or 2 h when 2-PAM was administered. It is well known that 2-PAM cannot effectively cross the BBB (<10%) (Kalasz et al., 2015; Sakurada et al., 2003; Shih et al., 2011) .
Also, in this study the same level of protection was observed using animals from two different suppliers (Charles River and Envigo), providing evidence of the reproducibility of the Oxime 20 efficacy data. In preliminary survival tests with lethal challenges of guinea pigs with sarin (conducted by a surety laboratory outside MSU), Oxime 20 displayed some efficacy against this live nerve agent for both 24-h survival and AChE reactivation, and alleviation of signs of toxicity.
Collectively, the data from this research indicated that Oxime 20 was capable of crossing the blood-brain barrier in sufficient amounts to effectively reactivate inhibited brain AChE, and offer protection from neural damage, unlike traditionally used oximes such as 2-PAM. Our assumption is that, unlike 2-PAM, the dampening of the brain hypercholinergic activity by Oxime 20 suppresses the glutamatergic excitotoxicity that would have resulted in seizures prolonged enough to produce neural damage.
Whereas the rationale for the synthesis of this substituted phenoxyalkyl pyridinium oxime platform was to increase lipophilicity for potentially greater brain penetration, the level of lipophilicity was not a predictive tool for the likelihood of an oxime crossing the BBB. Many oximes in our platform of novel oximes that were highly lipophilic and good reactivators of AChE in vitro failed to effectively reactivate AChE in the brain (Chambers et al., 2013) . These data suggest that the oximes showing efficacy in vivo may be being transported into the brain Figure 6 . Levels of glial fibrillary acidic protein (GFAP) 4 days after treatment with NIMP (0.325 mg/kg) or NEMP (0.4 mg/kg) were significantly higher (*p < 0.05; n ¼ 3-4) compared with control, Oxime MS, and respective surrogateþOxMS animals in both the piriform cortex and the dentate gyrus region of hippocampus. Note: OxMS is the mesylate salt of Oxime 20. Figure 7 . Levels of glial fibrillary acidic protein (GFAP) 4 days after treatment with NIMP (0.325 mg/kg, IP) or NIMP þ 2-PAM were significantly higher (*p < 0.05; n ¼ 3-4) compared with control and 2-PAM treated animals, in both the piriform cortex and the dentate gyrus region of the hippocampus. by affinity to an import transporter. However, an export transporter such as P-glycoprotein could remove oximes from the brain before they can be efficacious (Sharom, 2006 (Sharom, , 2011 . Recent results from our laboratories indicated that Oxime 20 is not an effective P-glycoprotein substrate (Dail et al., 2018) , which may be an important feature in its ability to provide protection within the brain.
The nerve agent surrogates used in this research effectively mimic the live nerve agents which they resemble. The surrogates caused neural damage in the experimental paradigm described here (when administered in levels to inhibit approximately 80% of brain AChE within an hour), as with live nerve agents. GFAP was an effective marker for documenting neuropathology in this rat model where animals are treated with these surrogates. Furthermore, the surrogates exhibit similar levels of damage in the same brain regions as KA, a well-documented positive control for seizure-induced neuropathology. The level of reactivation induced by Oxime 20 of surrogate inhibited AChE in the brain (up to 35% by 2 h) appears to be significant enough to provide protection from long-term neural damage. Therefore, the novel oxime chemistry used in this study provides promise of a better treatment after exposure to OPs, such as nerve agents, and may prevent or attenuate lasting damage to the brain after high dose OP exposure. This is the first report of the ability of this novel oxime platform to provide protection against OP-induced neuropathology. Our on-going studies are investigating additional neural markers using a more rigorous lethal level challenge of OP's. It is possible that use of an oxime such as Oxime 20 could be implemented to augment the effectiveness of the current therapy for organophosphate poisoning and render protection to the brain.
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